Healthcare
Oxford Nanopore Technologies plc(ONTTF)
Live Price
Offline$1.61
-2.60% today
1Y Change
-8.33%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $1.14B
- Revenue Growth
- +22.2%
- EPS Growth
- +6.3%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oxford Nanopore Technologies plc (ONTTF) is a Healthcare stock with a market cap of $1.14B and listed on OTC. The stock last traded around $1.61 and down 8.3% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +22.2%, EPS growth of +6.3%, a dividend yield of 0.0%. What stands out right now is revenue +22.2%, EPS +6.3%, free cash flow +58.2% with operating margin -69.4% and ROIC -30.5%. Valuation sits in the middle of the pack at price/sales 5.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ONTTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+22.2% vs +7.6% peer median
Operating Margin
Below sector median
-69.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 2, 2026 with an EPS surprise of -0.2% and a revenue surprise of +1.8%.
The operating story is still moving forward
Revenue is running at +22.2% and EPS at +6.3%, with operating margin around -69.4%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 19, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +14.2% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 2, 2026 | -0.2% | +4.4% | +13.9% | -3.2% |
2025 Sep 2, 2025 | +2.1% | +9.5% | +13.7% | +1.4% |
2025 Mar 4, 2025 | +20.3% | +10.1% | +14.9% | +68.5% |
Benchmark Edge
ONTTF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ONTTF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ONTTF Max Drawdown
-53.06%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ONTTF and SPY.
Company Overview
Oxford Nanopore Technologies plc
Other OTC
Oxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules. The company offers MinION, a portable device for deoxyribonucleic acid and ribonucleic acid sequencing; GridION, a self-contained benchtop device for running and analyzing up to five MinION or Flongle flow cells; MinION Mk1C for basecalling and data analysis, touchscreen operation, and wireless connectivity; Flongle, an adapter for use in MinION or GridION devices to attach a Flongle flow cell; GridION Mk1, a benchtop nanopore sequencer; PromethION 2 Solo and PromethION 2, a low-cost access to high-yield PromethION sequencing; PromethION 24 and PromethION 48 benchtop nanopore-based sequencers for multiple users to deliver multi-sample and multi-experiment sequencing results; and VolTRAX, an USB-powered device, which automates laboratory processes upstream of nanopore sequencing. It also provides MinKNOW, a software that offers data acquisition, real-time analysis and feedback, local basecalling, and data streaming; Basecalling tools to determine the identity and order of bases on the DNA/RNA molecule; EPI2ME, a cloud-based data analysis platform for end-to-end analysis of nanopore data in real time; and EPI2ME Labs, a bioinformatics solution to assist users in developing their skills and confidence in the analysis of their nanopore-based sequencing data. In addition, the company is developing MinION Mk1D; Ubi; Plongle; and SmidgION products. It sells its products online. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is based in Oxford, the United Kingdom.
- Leadership
- Francis Albert Luc Van Parys
- IPO Date
- Oct 15, 2021
- Employees
- 1.4k
- Street Address
- Gosling Building
- Mailing
- Oxford, OX4 4DQ
- Region
- Oxford, GB
- Reporting Currency
- USD
- Investor Line
- 44 84 5034 7900
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.1
- Price/Book
- 2.4
Growth
- Revenue
- +22.2%
- EPS
- +6.3%
- Free Cash Flow
- +58.2%
Profitability
- Gross Margin
- 58.6%
- Operating Margin
- -69.4%
- Net Margin
- -64.9%
- ROE
- -29.4%
- ROIC
- -30.5%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 3.56
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.